Focused On-demand Library for Melanocortin-2 receptor accessory protein

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q8TCY5

UPID:

MRAP_HUMAN

Alternative names:

B27; Fat cell-specific low molecular weight protein; Fat tissue-specific low MW protein

Alternative UPACC:

Q8TCY5; Q5EBR3; Q8TDB7; Q8WXC1; Q8WXC2

Background:

The Melanocortin-2 Receptor Accessory Protein (MRAP), known by alternative names such as B27 and Fat tissue-specific low MW protein, plays a pivotal role in modulating melanocortin receptors (MC1R to MC5R). It enhances ligand sensitivity and cAMP generation, crucial for MC2R trafficking and ACTH response in adrenal cells, and may influence adipocyte intracellular pathways.

Therapeutic significance:

Linked to Glucocorticoid deficiency 2, a disorder marked by adrenal insufficiency and cortisol production failure, understanding MRAP's function could unveil new therapeutic avenues. Its involvement in ACTH receptor modulation and adrenal cortex activity highlights its potential in treating cortisol deficiency-related conditions.